Skip to main content

Table 1 Patients’ characteristics

From: Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

 

Patients

Controls

Total

VMP

VMPT

n

124

53

71

54

Age

71 (56–85)

71 (60–85)

71 (56–85)

69 (54–88)

Sex (M/F)

58/66

24/29

34/37

24/30

Type of MM

NA

 IgG (%)

71 (57.2)

31 (58.5)

46 (64.8)

 

 IgA (%)

28 (22.6)

12 (22.6)

14 (19.8)

 

 BJ (%)

25 (20.2)

10 (18.9)

11 (15.4)

 

Stage (D&S)

NA

 IIA (%)

14 (11.3)

5 (9.4)

9 (12.7)

 

 IIIA (%)

102 (82.3)

45 (84.9)

57 (80.3)

 

 IIIB (%)

8 (6.4)

3 (5.7)

5 (7)

 

ISS stage

NA

 1

26

8

18

 

 2

42

21

21

 

 3

21

6

15

 

 Missing data

35

18

17

 

Cytogenetics

NA

 High risk

28

11

17

 

 Standard risk

36

16

20

 

 Missing data

60

26

34

 

Response

 CR (%)

47 (37.9)

14 (26.4)

33 (46.6)

 

 VGPR (%)

27 (21.8)

11 (20.8)

16 (22.6)

NA

 PR (%)

38 (30.6)

19 (35.8)

19 (26.8)

 

 SD (%)

12 (9.7)

9 (17)

3 (4.2)

 

Relapse (Y/N)

80/44

39/14

41/30

NA

Death (Y/N)

54/70

22/31

32/39

NA

  1. NA not applicable